Jefferies analyst issues BUY recommendation for VSTM on October 14, 2026 08:03PM ET. The previous analyst recommendation was Buy.VSTM was trading at $7.71 at issue of the analyst recommendation.The overall analyst consensus : BUY.Current analyst recommendations are : 15 - Buy, 4 - Hold recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport DateAnalyst CompanyActionPrevious GradeNew GradePrice when...
Jason Kreyer from Craig-Hallum issued a price target of $22.00 for PRCH on 2026-10-14 13:01:15.The adjusted...
Mike Grondahl from Northland Securities issued a price target of $13.25 for MFIN on 2026-10-14 12:45:12.The...
Craig-Hallum analyst issues BUY recommendation for PRCH on October 14, 2026 01:01PM ET. The previous analyst...
Eric Sheridan from Goldman Sachs issued a price target of $43.00 for LIFE on 2026-10-14 11:15:04.The...
Jason Kreyer from Craig-Hallum issued a price target of $22.00 for PRCH on 2026-10-14 13:01:15.The adjusted price target was set to $22.00.At the time of the announcement, PRCH was trading...
Mike Grondahl from Northland Securities issued a price target of $13.25 for MFIN on 2026-10-14 12:45:12.The adjusted price target was set to $13.25.At the time of the announcement, MFIN was...
Eric Sheridan from Goldman Sachs issued a price target of $43.00 for LIFE on 2026-10-14 11:15:04.The adjusted price target was set to $43.00.At the time of the announcement, LIFE was...
from Industrial Alliance Securities issued a price target of $21.50 for PINE on 2026-10-14 11:03:16.The adjusted price target was set to $21.50.At the time of the announcement, PINE was trading...
Yi Chen from H.C. Wainwright issued a price target of $18.00 for ANGO on 2026-10-13 16:08:25.The adjusted price target was set to $18.00.At the time of the announcement, ANGO was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
